A joint supplement millions take is linked to faster Alzheimer's progression

Most warnings about a joint supplement focus on the joints: does it work, does it interact with a blood thinner. A study published this year asks a different question about glucosamine, aimed at the brain instead of the knee.

The study

A research team at the University of Florida, including biomedical data scientists Yi Guo and Jiang Bian and UF biochemistry chair Matt Gentry, used an AI tool to comb through twelve years of de-identified UF Health electronic records, from 2012 to 2024, covering roughly 41,000 patients with mild cognitive impairment (MCI) and roughly 24,000 with a dementia diagnosis. They compared people who took glucosamine against people who did not, tracking who progressed from MCI to Alzheimer's disease, and separately tracking survival among people who already had an Alzheimer's or related dementia diagnosis.

Alongside the records analysis, the team ran a parallel line of lab work: spatial metabolomics and lipidomics on post-mortem human brain tissue, and experiments in a transgenic mouse model of Alzheimer's disease. The combined paper, "Hyperglycosylation is a metabolic driver of Alzheimer's disease," was published in Nature Metabolism in June 2026.

The finding

People with MCI who took glucosamine were 25% more likely to progress to Alzheimer's disease than those who did not. Among people who already had an Alzheimer's or related dementia diagnosis, glucosamine use was linked to a 25% higher mortality risk over the study's follow-up.

The lab side of the paper points at a specific mechanism. Brain tissue from people who had Alzheimer's, and from mice engineered to develop it, showed a buildup of abnormal sugar-tagging on proteins, a process called hyperglycosylation, concentrated in brain regions involved in memory. In the mouse model, giving oral glucosamine made cognitive performance worse, while experimentally suppressing the enzymes that build those sugar tags improved it. Glucosamine is itself a sugar-related molecule that crosses the blood-brain barrier, which gives the records finding a plausible biological story rather than leaving it as a bare statistical association.

What this design can and cannot tell you

This is a retrospective analysis of health records, not a trial that assigned some people to take glucosamine and others not to. The researchers themselves describe the finding as needing to be tested in a clinical trial before it counts as proof, and outside reviewers have raised a specific, hard-to-dismiss concern: people who take glucosamine mostly take it for osteoarthritis joint pain, and joint pain tracks with reduced mobility and frailty, both independently linked to dementia risk. The published analysis adjusted for age, sex and demographics, but critics, including commentary from the Natural Products Association reported by trade press, have argued it does not fully account for mobility, frailty or diet, which means some of the association could reflect who takes glucosamine rather than what glucosamine does.

There is also a more direct complication. A 2023 study using UK Biobank data, more than 340,000 people free of dementia at the start, followed for a median of 8.9 years, found the opposite pattern: regular glucosamine users had a lower risk of developing all-cause dementia (hazard ratio 0.84), Alzheimer's disease (0.83) and vascular dementia (0.74), and a Mendelian randomization analysis in the same paper suggested the association might even be causal in that direction.

That study and the new one are not quite answering the same question. The UK Biobank work asked whether glucosamine use predicts who develops dementia in the first place, in people who did not have it yet. The UF work asked whether, among people who already have cognitive impairment, glucosamine use predicts faster decline and worse survival. Prevention and progression are different questions, and it is possible for a single supplement to show different patterns across them. But it means the honest summary is that the evidence is mixed and the newest finding has a real proposed mechanism behind it, not that glucosamine has been shown to cause Alzheimer's disease.

Getting glucosamine

Glucosamine is not meaningfully present in an ordinary diet. The glucosamine in a supplement bottle is manufactured, typically extracted from the shells of shrimp, crab or lobster as glucosamine sulfate or glucosamine hydrochloride, or produced by fermenting corn or wheat for a shellfish-free version. Bone broth and other cartilage-rich cooking carry trace amounts, well below a supplement dose and not quantified in standard food composition databases. There is no realistic way to reach a meaningful intake through food the way you can with iron or vitamin C, which is why this section does not carry a ranked list of foods. If you take glucosamine, it almost certainly comes from a bottle, not a plate.

How much people take

The body makes its own glucosamine to help maintain cartilage, so ordinary diet creates no shortfall to correct, which is why there is no RDA, AI or upper limit set for it the way there is for an essential nutrient. The typical over-the-counter dose is 1,500 mg a day of glucosamine sulfate or hydrochloride, taken as one dose or split through the day with food, with some products going up to 3,000 mg. A systematic review of the safety evidence has found it generally well tolerated at intakes up to roughly 2,000 mg a day. An estimated 6.5 million US adults, about 2.6% of the population, take glucosamine, chondroitin or both, mostly for osteoarthritis.

Too little, and too much

Too little is not a real category here. Glucosamine is not an essential nutrient, the body synthesizes what it needs for its own cartilage maintenance, and there is no deficiency state to watch for.

Too much, or simply taking it at all, is where this year's finding sits, alongside a smaller existing list of concerns. A separate, earlier observational study of 685,778 osteoarthritis patients linked glucosamine use to a higher rate of cardiovascular disease. Documented side effects at ordinary doses are mild and mostly digestive: nausea, diarrhea and heartburn. Most glucosamine is derived from shellfish shells, so people with a shellfish allergy should check the source or choose a fermentation-derived version. Case reports have linked high-dose glucosamine to increased bruising and bleeding in people taking warfarin, and some clinicians advise caution for people with diabetes, glaucoma or impaired liver function, though the evidence behind those specific cautions is thinner than the warfarin interaction.

None of this adds up to "stop taking it." It adds up to: if you have a diagnosis of mild cognitive impairment or an established dementia, this is now a specific, evidence-based question to bring to whoever manages that diagnosis, rather than a decision to make alone based on a headline.

Tracking it in AIM

AIM does not track glucosamine as standard, so add it as a custom metric: give it a name, a unit (mg, or just a yes/no if you would rather log whether you took your dose) and a daily target matching what you actually take, commonly 1,500 mg, and it is estimated on every meal from then on, pinned to your cards or left behind "more".

Estimates from a photograph carry real uncertainty for micronutrients, because content varies with soil, cultivar, storage and cooking in ways no image contains. Glucosamine does not come from a plate in the first place, so the honest use of a custom metric here is a log of the dose you took, not a photo estimate. Treat the week as meaningful and any single day as approximate.